drugset / Trial / NCT04244591

Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure

NCT04244591

RandomizedParallel-groupOpen-labelTreatment

Summary

In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure.

Timeline

Start
2020-01-26
Primary completion
2020-04-13
Completion
2020-04-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 40 mg

Indications